- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Immunomedics CEO DeLuccia departs
Radiopharmaceutical firm Immunomedics of Morris Plains, NJ, in June announced the resignation of Robert DeLuccia, the company’s president, CEO, and director. DeLuccia began his tenure at Immunomedics in June 1998, when he took over duties previously
Radiopharmaceutical firm Immunomedics of Morris Plains, NJ, in June announced the resignation of Robert DeLuccia, the companys president, CEO, and director. DeLuccia began his tenure at Immunomedics in June 1998, when he took over duties previously handled by the companys founder, Dr. David Goldenberg (SCAN 6/10/98). Dr. Goldenberg will resume the position of CEO, according to the company.
In other Immunomedics management moves, Philippe Barzin, general manager of Immunomedics Europe, will relocate to the companys U.S. headquarters and assume the post of vice president for global marketing and business development.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.
